208 related articles for article (PubMed ID: 32193075)
1. S100 Soil Sensor Receptors and Molecular Targeting Therapy Against Them in Cancer Metastasis.
Tomonobu N; Kinoshita R; Sakaguchi M
Transl Oncol; 2020 Apr; 13(4):100753. PubMed ID: 32193075
[TBL] [Abstract][Full Text] [Related]
2. exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.
Kinoshita R; Sato H; Yamauchi A; Takahashi Y; Inoue Y; Sumardika IW; Chen Y; Tomonobu N; Araki K; Shien K; Tomida S; Torigoe H; Namba K; Kurihara E; Ogoshi Y; Murata H; Yamamoto KI; Futami J; Putranto EW; Ruma IMW; Yamamoto H; Soh J; Hibino T; Nishibori M; Kondo E; Toyooka S; Sakaguchi M
Int J Cancer; 2019 Jun; 144(12):3138-3145. PubMed ID: 30365872
[TBL] [Abstract][Full Text] [Related]
3. exMCAM-Fc, an S100A8/A9-mediated-metastasis blocker, efficiently reduced the number of circulating tumor cells that appeared in the blood flow.
Tomonobu N; Kinoshita R; Sakaguchi M
Mol Biol Rep; 2020 Jun; 47(6):4879-4883. PubMed ID: 32383137
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
Chen Y; Sumardika IW; Tomonobu N; Winarsa Ruma IM; Kinoshita R; Kondo E; Inoue Y; Sato H; Yamauchi A; Murata H; Yamamoto KI; Tomida S; Shien K; Yamamoto H; Soh J; Liu M; Futami J; Sasai K; Katayama H; Kubo M; Putranto EW; Hibino T; Sun B; Nishibori M; Toyooka S; Sakaguchi M
Cancer Lett; 2019 Jun; 452():178-190. PubMed ID: 30904617
[TBL] [Abstract][Full Text] [Related]
5. Neuroplastin-β mediates S100A8/A9-induced lung cancer disseminative progression.
Sumardika IW; Chen Y; Tomonobu N; Kinoshita R; Ruma IMW; Sato H; Kondo E; Inoue Y; Yamauchi A; Murata H; Yamamoto KI; Tomida S; Shien K; Yamamoto H; Soh J; Futami J; Putranto EW; Hibino T; Nishibori M; Toyooka S; Sakaguchi M
Mol Carcinog; 2019 Jun; 58(6):980-995. PubMed ID: 30720226
[TBL] [Abstract][Full Text] [Related]
6. β-1,3-Galactosyl-
Sumardika IW; Youyi C; Kondo E; Inoue Y; Ruma IMW; Murata H; Kinoshita R; Yamamoto KI; Tomida S; Shien K; Sato H; Yamauchi A; Futami J; Putranto EW; Hibino T; Toyooka S; Nishibori M; Sakaguchi M
Oncol Res; 2018 Apr; 26(3):431-444. PubMed ID: 28923134
[TBL] [Abstract][Full Text] [Related]
7. Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.
Kinoshita R; Sato H; Yamauchi A; Takahashi Y; Inoue Y; Sumardika IW; Chen Y; Tomonobu N; Araki K; Shien K; Tomida S; Torigoe H; Namba K; Kurihara E; Ogoshi Y; Murata H; Yamamoto KI; Futami J; Putranto EW; Ruma IMW; Yamamoto H; Soh J; Hibino T; Nishibori M; Kondo E; Toyooka S; Sakaguchi M
Int J Cancer; 2019 Jul; 145(2):569-575. PubMed ID: 30414170
[TBL] [Abstract][Full Text] [Related]
8. S100A8, S100A9 and the S100A8/A9 heterodimer complex specifically bind to human endothelial cells: identification and characterization of ligands for the myeloid-related proteins S100A9 and S100A8/A9 on human dermal microvascular endothelial cell line-1 cells.
Eue I; König S; Pior J; Sorg C
Int Immunol; 2002 Mar; 14(3):287-97. PubMed ID: 11867565
[TBL] [Abstract][Full Text] [Related]
9. MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.
Ruma IM; Putranto EW; Kondo E; Murata H; Watanabe M; Huang P; Kinoshita R; Futami J; Inoue Y; Yamauchi A; Sumardika IW; Youyi C; Yamamoto K; Nasu Y; Nishibori M; Hibino T; Sakaguchi M
Clin Exp Metastasis; 2016 Aug; 33(6):609-27. PubMed ID: 27151304
[TBL] [Abstract][Full Text] [Related]
10. Identification of an S100A8 Receptor Neuroplastin-β and its Heterodimer Formation with EMMPRIN.
Sakaguchi M; Yamamoto M; Miyai M; Maeda T; Hiruma J; Murata H; Kinoshita R; Winarsa Ruma IM; Putranto EW; Inoue Y; Morizane S; Huh NH; Tsuboi R; Hibino T
J Invest Dermatol; 2016 Nov; 136(11):2240-2250. PubMed ID: 27388991
[TBL] [Abstract][Full Text] [Related]
11. Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness.
Chen Y; Sumardika IW; Tomonobu N; Kinoshita R; Inoue Y; Iioka H; Mitsui Y; Saito K; Ruma IMW; Sato H; Yamauchi A; Murata H; Yamamoto KI; Tomida S; Shien K; Yamamoto H; Soh J; Futami J; Kubo M; Putranto EW; Murakami T; Liu M; Hibino T; Nishibori M; Kondo E; Toyooka S; Sakaguchi M
Neoplasia; 2019 Jul; 21(7):627-640. PubMed ID: 31100639
[TBL] [Abstract][Full Text] [Related]
12. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion.
Ryckman C; Vandal K; Rouleau P; Talbot M; Tessier PA
J Immunol; 2003 Mar; 170(6):3233-42. PubMed ID: 12626582
[TBL] [Abstract][Full Text] [Related]
13. Secretion of the Phosphorylated Form of S100A9 from Neutrophils Is Essential for the Proinflammatory Functions of Extracellular S100A8/A9.
Schenten V; Plançon S; Jung N; Hann J; Bueb JL; Bréchard S; Tschirhart EJ; Tolle F
Front Immunol; 2018; 9():447. PubMed ID: 29593718
[TBL] [Abstract][Full Text] [Related]
14. Intracellular expression of inflammatory proteins S100A8 and S100A9 leads to epithelial-mesenchymal transition and attenuated aggressivity of breast cancer cells.
Cormier K; Harquail J; Ouellette RJ; Tessier PA; Guerrette R; Robichaud GA
Anticancer Agents Med Chem; 2014 Jan; 14(1):35-45. PubMed ID: 24041228
[TBL] [Abstract][Full Text] [Related]
15. Differential release and deposition of S100A8/A9 proteins in inflamed upper airway tissue.
Van Crombruggen K; Vogl T; Pérez-Novo C; Holtappels G; Bachert C
Eur Respir J; 2016 Jan; 47(1):264-74. PubMed ID: 26493794
[TBL] [Abstract][Full Text] [Related]
16. S100a8/a9 Signaling Causes Mitochondrial Dysfunction and Cardiomyocyte Death in Response to Ischemic/Reperfusion Injury.
Li Y; Chen B; Yang X; Zhang C; Jiao Y; Li P; Liu Y; Li Z; Qiao B; Bond Lau W; Ma XL; Du J
Circulation; 2019 Aug; 140(9):751-764. PubMed ID: 31220942
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer.
Grebhardt S; Veltkamp C; Ströbel P; Mayer D
Int J Cancer; 2012 Dec; 131(12):2785-94. PubMed ID: 22505354
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.
Wagner NB; Weide B; Gries M; Reith M; Tarnanidis K; Schuermans V; Kemper C; Kehrel C; Funder A; Lichtenberger R; Sucker A; Herpel E; Holland-Letz T; Schadendorf D; Garbe C; Umansky V; Utikal J; Gebhardt C
J Immunother Cancer; 2019 Dec; 7(1):343. PubMed ID: 31806053
[TBL] [Abstract][Full Text] [Related]
19. S100A8/A9 in Inflammation.
Wang S; Song R; Wang Z; Jing Z; Wang S; Ma J
Front Immunol; 2018; 9():1298. PubMed ID: 29942307
[TBL] [Abstract][Full Text] [Related]
20. The effects of a randomized trial of brief forms of stress management on RAGE-associated S100A8/A9 in patients with breast cancer undergoing primary treatment.
Taub CJ; Lippman ME; Hudson BI; Blomberg BB; Diaz A; Fisher HM; Nahin ER; Lechner SC; Kwak T; Hwang GH; Antoni MH
Cancer; 2019 May; 125(10):1717-1725. PubMed ID: 30633331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
